Internal Medicine, Medical Oncology · Estero, FL
NPI
1841209426
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
8440 Murano del Lago Dr
Estero, FL, 34135
Phone (239) 221-5402
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.9M
275,951 services
Medicare patients, 2024
1,204
Average age 77
Drug cost, 2024
$2.2M
1,036 prescriptions
Company payments, 2025
$1,050
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Susanna S Gaikazian was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 45,900 times for 64 patients. In total Susanna S Gaikazian billed 275,951 services in 147 codes, and Medicare paid $3.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-28.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 45,900 | 64 | $0.27 | $13K |
| J9025 Injection, azacitidine, 1 mg | Office | 33,150 | 12 | $0.30 | $9,924 |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 21,180 | 12 | $0.22 | $4,584 |
| J1756 Injection, iron sucrose, 1 mg | Office | 17,200 | 30 | $0.18 | $3,046 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,600 | 21 | $44.57 | $651K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 8,550 | 36 | $6.38 | $55K |
| J0185 Injection, aprepitant, 1 mg | Office | 8,320 | 22 | $1.33 | $11K |
| J0897 Injection, denosumab, 1 mg | Office | 7,560 | 76 | $20.73 | $157K |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,284 | 12 | $0.08 | $587 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,726 | 19 | $35.36 | $132K |
| 85025 Blood Count | Office | 2,182 | 744 | $7.61 | $17K |
| 36415 Venipuncture Blood Collection | Office | 2,045 | 748 | $8.65 | $18K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,844 | 64 | $0.09 | $167 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,260 | 36 | $0.76 | $954 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,130 | 13 | $5.75 | $6,501 |
By year: 2022 $1.4M for 133,841 services; 2023 $3.2M for 272,212 services; 2024 $3.9M for 275,951 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,182 | 744 | $7.61 | $17K |
| 36415 Venipuncture Blood Collection | 2,045 | 748 | $8.65 | $18K |
| 81003 Clinical Chemistry | 61 | 14 | $2.20 | $134 |
| 85046 Blood Count | 43 | 36 | $5.46 | $235 |
| 85045 Blood Count | 15 | 15 | $3.91 | $58.65 |
Medicare prescription drug claims, 2024
In 2024, the drug Susanna S Gaikazian prescribed most often to Medicare patients was Anastrozole, with 199 prescriptions and refills. In total Susanna S Gaikazian wrote 1,036 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 199 | 506 | 63 | $3,634 |
| Hydroxyurea Generic | 89 | 209 | 23 | $3,822 |
| Eliquis Apixaban | 81 | 110 | 16 | $65K |
| Letrozole Generic | 60 | 162 | 22 | $1,616 |
| Ondansetron Odt Ondansetron | 33 | 33 | 25 | $754 |
| Dexamethasone Generic | 31 | 34 | 11 | $416 |
| Xarelto Rivaroxaban | 30 | 52 | Under 11 | $29K |
| Revlimid Lenalidomide | 30 | 30 | Under 11 | $523K |
| Kisqali Ribociclib Succinate | 27 | 27 | Under 11 | $409K |
| Prednisone Generic | 25 | 25 | 15 | $132 |
| Acyclovir Generic | 22 | 35 | Under 11 | $154 |
| Gabapentin Generic | 21 | 25 | Under 11 | $181 |
| Ondansetron Hcl Generic | 18 | 19 | Under 11 | $292 |
| Kisqali Femara Co-Pack Ribociclib Succinate/Letrozole | 14 | 14 | Under 11 | $234K |
| Lorazepam Generic | 13 | 13 | Under 11 | $66.22 |
Brand drugs: 237 claims; generic drugs: 799 claims; opioid claims: 43.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Susanna S Gaikazian $1,050 ($1,050 in general payments such as food, travel and fees) from 23 companies. The largest payer was Merck Sharp & Dohme LLC with $151.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 3 | $151 |
| Abbvie Inc. ABBV | 5 | $116 |
| Daiichi Sankyo Inc. 4568.T | 3 | $78.61 |
| Array Biopharma Inc PFE | 3 | $69.94 |
| Celgene Corporation BMY | 3 | $62.12 |
| BeOne Medicines USA, Inc. ONC | 2 | $58.08 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $56.56 |
| Incyte Corporation INCY | 2 | $49.19 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $45.81 |
| Janssen Biotech, Inc. JNJ | 2 | $42.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.